This guideline describes strategies for pre-treatment assessment and modulation of immunosuppression in patients with post-transplant lymphoproliferative disease (PTLD). The guidance considers specific types of PTLD and the relative roles of systemic chemotherapy, rituximab, surgery and radiotherapy.
Correction: on p697, column 2 of the BJH article, a recommendation describes a risk factor as being age <60 years. It should read >60 years.
Please also see the guideline on the diagnosis of PTLD.
This guideline has an update please see the information below.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.